BriaCell Therapeutics Corp. has announced the pricing for a public offering consisting of 762,500 common shares, priced at $4.00 each. The company anticipates raising total gross proceeds of $3.05 million from this offering, prior to the deduction of placement agent fees and other related expenses. The completion of the offering is scheduled for February 5, 2025. BriaCell plans to allocate the net proceeds towards meeting working capital needs, supporting general corporate purposes, and furthering its business goals.